Cardio-oncology is an emerging field that aims to ensure optimal cancer treatment while minimising cardiovascular toxicity. The management of cardiovascular toxicity is critical because it can lead to premature discontinuation of treatment, increasing the risk of cancer recurrence and mortality. The 2022 European Society of Cardiology guidelines were a milestone in advocating a patient-centred, multidisciplinary approach. Key components include risk stratification and a standardised criterion for adverse events, incorporating definitions from the International Cardio-Oncology Society. Effective risk stratification, supported by imaging and biomarkers, helps to anticipate cardiovascular problems and implement preventive measures. Future research should focus on understanding mechanisms, developing preventive strategies and implementing personalised medicine. Education and reducing disparities in care are essential to advance cardio-oncology and improve patient outcomes.

心脏肿瘤学是一个新兴领域，旨在确保最佳的癌症治疗，同时最大限度地减少心血管毒性。心血管毒性的管理至关重要，因为它可能导致过早停止治疗，增加癌症复发和死亡的风险。 2022 年欧洲心脏病学会指南是倡导以患者为中心的多学科方法的里程碑。关键组成部分包括风险分层和不良事件的标准化标准，并纳入国际心脏肿瘤学会的定义。在影像学和生物标志物的支持下，有效的风险分层有助于预测心血管问题并实施预防措施。未来的研究应侧重于理解机制、制定预防策略和实施个性化医疗。教育和减少护理差异对于推进心脏肿瘤学和改善患者治疗效果至关重要。